UCHL5

Across TCGA pan-cancer cohorts, UCHL5 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated UCHL5 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher UCHL5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UCHL5 expression acts as an unfavorable survival marker.

LUAD, MESO, and HNSC are the cancer types where UCHL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.205	0.672	<.001	43	view →
MESO	OS	Median	II,III,IV	0.071	0.572	<.001	24	view →
HNSC	DFS	Median	All	0.165	0.626	.018	21	view →
ESCA	OS	Median	All	0.095	0.701	<.001	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

UCHL5–LUAD (OS)

Open the LUAD breakdown →